The selective IRE1 RNase inhibitor B-I09 hindered the transmembrane receptor for IRE1, showing efficacy in inhibiting leukemia progression without systemic toxicity in a mouse model of chronic lymphocytic leukemia (CLL)(Tang et al. 2014). This evidence concerns the gene NRP1 and B-cell chronic lymphocytic leukemia.